Understanding Severe Epilepsies

For those dealing with a rare and severe form of epilepsy, the path to an accurate diagnosis can be lengthy, with nearly 5 years of uncontrolled seizures from the onset. In some cases, individuals may reach adulthood without a precise diagnosis, despite suffering from conditions like Lennox-Gastaut syndrome (LGS), Dravet Syndrome (DS), or Tuberous Sclerosis Complex (TSC). Waiting this long shouldn’t be the norm.

Obtaining an early diagnosis can make a world of difference. It can unlock access to various treatment options.

Why do many people not get diagnosed?

Some seizure disorders like Lennox-Gastaut syndrome (LGS), Dravet Syndrome (DS), and Tuberous Sclerosis Complex (TSC) can be tricky to identify. The signs might look like other problems, and they can be different for each person, sometimes even changing in the same person over time.

The Significance of Timely Diagnosis, Awareness, and Treatment"

Early identification of seizures is pivotal, as it enables healthcare professionals an effective treatment strategy, which could involve genetic testing.

Unnoticed or unmanaged seizures are associated with adverse long-term consequences such as developmental disabilities, learning difficulties, and behavioral disorders.

Seizures associated with Lennox-Gastaut syndrome (LGS), Dravet Syndrome (DS), Tuberous Sclerosis Complex (TSC), we recommend seeking out a specialized healthcare provider, clinic, or a recognized center of excellence. They can offer expertise to ensure the best possible care.

Our Commitment to Seizure Management

We understand the immense physical and emotional toll that frequent seizures can have on individuals and their families. That's why developed solutions that significantly reduce seizures in people facing the most challenging seizure disorders.

Treatment for Seizure

Clasepi represents a breakthrough in seizure management for those living with LGS, Dravet syndrome or TSC. We've carefully crafted our treatment to target the specific needs of these conditions, recognizing that traditional antiseizure medicines may not always provide the desired relief

Clasepi : Bring Back the Normalcy

Proven Efficacy

Our treatment has shown to significantly reduce seizures in individuals who have not experienced success with multiple antiseizure medicines.

Personalized Care

We understand that each person's journey with LGS, Dravet syndrome, or TSC is unique. That's why we work closely with healthcare professionals.

Hope for the Future

Clasepi is more than just a treatment; it's a source of hope for those who may have felt discouraged by previous unsuccessful attempts to control their seizures. We believe in a brighter future for everyone have seizures

Your Journey to Seizure Control Starts Here

If you or a loved one have been searching for a solution to reduce seizures and regain control over life, Clasepi is here to offer a helping hand. 

Don't let seizures define your life any longer. Explore the possibilities with Clasepi and take the first step toward a seizure-free future.

what defines us

Mission

Transforming the lives of people with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) Tuberous sclerosis complex (TSC) and to facilitate therapies to stop seizures , Better quality of life, Educate & reduce close relatives emotional burden

Values

Life without Seizures. Enjoy the precious moments of life. Access to society , education and employment.

Uniqueness

• First time available in India
• 100% synthetic CBD - consistent quality
• Free from THC (<0.1%)
• Non-Intoxicating

How it Work

Clasepi Results

Clasepi significantly reduced seizures in people living with LGS, Dravet syndrome, or TSC for whom multiple previous antiseizure medicines did not work well well.

Learn more

Getting started on Clasepi

Learn about filling your prescription, dosing, administration, and more.

Learn more

Helpful resources

Learn more about CBD, and download a product information

Learn more

FAQs

Cannabidiol is a prescription medicine that is used to treat seizures associated with Lennox-Gastaut Syndrome, Dravet Syndrome and/ or Tuberous Sclerosis Complex in people 1 year of age and older.  

  • Take Clasepi exactly as your healthcare provider tells you.
  • Your healthcare provider will tell you how much Clasepi to take and when to take it.
  • Measure each dose of Cannabidiol using the appropriate dosing syringes that come with Clasepi.

Clasepi may cause liver problems. Your healthcare provider may order blood tests to check your liver before you start taking Clasepi and during treatment. In some cases,Clasepi treatment may need to be stopped. Call your healthcare provider right away if you develop any of these signs and symptoms of liver problems during treatment with Cannabidiol:

  • loss of appetite, nausea, vomiting
  • fever, feeling unwell, unusual tiredness
  • yellowing of the skin or the whites of the eyes (jaundice)
  • itching
  • unusual darkening of the urine
  • right upper stomach area pain or discomfort

Clasepi may cause you to feel sleepy, which may get better over time.

Like other antiepileptic drugs, Clasepi may cause suicidal thoughts or actions in a very small number of people.  

These are not all of the possible side effects of Cannabidiol. For more information, ask your healthcare provider.

Tell your healthcare provider about any side effect that bothers you or that does not go away. Call your doctor for medical advice about side effects

Do not drive, operate heavy machinery, or do other dangerous activities until you know how Cannabidiol affects you. Cannabidiol may cause you to feel sleepy.

Do not take Clasepi if you are allergic to cannabidiol or any of the ingredients in Cannabidiol.

Do not stop taking Clasepi without first talking to your healthcare provider. Stopping a seizure medicine such as Clasepi suddenly can cause you to have seizures more often or seizures that do not stop (status epilepticus).

Call your healthcare provider between visits as needed, especially if you are worried about symptoms.  

If you have or had depression, mood problems or suicidal thoughts or behavior.
• have liver problems.
• have abused or been dependent on prescription medicines, street drugs or alcohol.

  • Store Clasepi at temperature mentioned on bottle pack.
  • Always store Clasepi in an upright position.
  • Do not freeze.
  • Keep the cap tightly closed.
  • Use Clasepi within 12 weeks of first opening the bottle. Throw away (dispose of) any unused medicine after 12 weeks.

Keep Clasepi out of the reach of children

504, 5th floor, G-Corp Tech Park, Near Hypercity, Owale, Thane West, Maharashtra 400615

022 – 61146000
Give us a Call

customercare@myakumentis.com
24/7 online support

Important safety information while taking CLASEPI

What is the Most Important Information I Should Know About CLASEPI (cannabidiol)?

Do not take if you are allergic to cannabidiol or any of the ingredients in CLASEPI (cannabidiol).

CLASEPI (cannabidiol) may cause liver problems. Your doctor may order blood tests to check your liver before you start taking CLASEPI (cannabidiol) and during treatment. In some cases, CLASEPI (cannabidiol) treatment may need to be stopped. Call your doctor right away if you start to have any of these signs and symptoms of liver problems during treatment with CLASEPI (cannabidiol):

  • loss of appetite, nausea, vomiting
  • fever, feeling unwell, unusual tiredness
  • yellowing of the skin or the whites of the eyes (jaundice)
  • itching
  • unusual darkening of the urine
  • right upper stomach area pain or discomfort

Side effects-

1. Hepatocellular Injury

Cannabidiol can cause dose-related elevations of liver transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]).

2. Somnolence and Sedation

Cannabidiol can cause somnolence and sedation. Prescribers should monitor patients for somnolence and sedation and should advise patients not to drive or operate machinery until they have gained sufficient experience on Cannabidiol to gauge whether it adversely affects their ability to drive or operate machinery.

3. Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including Cannabidiol, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with an AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behaviour.

4. Hypersensitivity Reactions

Cannabidiol can cause hypersensitivity reactions. Cannabidiol is contraindicated in patients with a prior hypersensitivity reaction to cannabidiol or any of the ingredients in the product, which includes sesame seed oil.

5. Withdrawal of Antiepileptic Drugs (AEDs)

As with most antiepileptic drugs, Cannabidiol should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. But if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered.

Precautions

  • Can cause hepatic transaminase elevations
  • Monitor for Somnolence and sedation.
  • Monitor patients for suicidal behavior and thoughts
  • Hypersensitivity Reactions
  • For Withdrawal of Antiepileptic Drugs Cannabidiol should be gradually withdrawn to minimize the risk of increased seizure frequency and status epilepticus.
 

Effects on ability to drive and use machines:

Cannabidiol has major influence on the ability to drive and operate machines because it may cause somnolence and sedation. Patients should be advised not to drive or operate machinery until they have gained sufficient experience to gauge whether it adversely affects their abilities.

Use in Specific Population:

  • Paediatrics: Safety and effectiveness of cannabdiol in children aged below 1 year have not been established.
  • Pregnancy: There are no adequate data on the developmental risks associated with the use of cannabidiol in pregnant women.
  • Breast-feeding: There are no data on the presence of cannabidiol or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.
  • Geriatric Use: Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
  • Hepatic Impairment: Because of an increase in exposure to cannabididol, dosage adjustments are necessary in patients with moderate or severe hepatic impairment.
  • Renal impairment: Cannabidiol can be administered to patients with mild, moderate, or severe renal impairment without dose adjustment. There is no experience in patients with end-stage renal disease. It is not known if cannabidiol is dialysable.

Contraindication:

Cannabidiol is contraindicated in patients with a history of hypersensitivity to cannabidiol or any of the ingredients in the product.

 

Overdose

Symptoms

Experience with doses higher than the recommended therapeutic dose is limited. Mild to moderate diarrhoea and somnolence have been reported in healthy adult subjects taking a single dose of 6000 mg; this equates to a dose of over 85 mg/kg for a 70 kg adult. These adverse reactions resolved upon study completion.

Management of overdose

In the event of overdose, the patient should be observed and appropriate symptomatic treatment given, including monitoring of vital signs